Argenica Therapeutics is developing neuroprotective therapeutics that target specific molecular pathways to enhance neuronal survival and reduce brain damage after a stroke. This approach aims to minimize neurological impairment and promote recovery, ultimately improving patient outcomes.
Funding
$835.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Stroke and other brain injuries result in significant neuronal cell death, leading to lasting brain damage, long-term disability, and even death for millions worldwide. Current treatments have limited efficacy in preventing this initial damage and promoting subsequent recovery.
Solution
Argenica Therapeutics is developing ARG-007, a novel peptide-based therapeutic designed to protect brain cells and reduce cell death following acute brain injuries such as stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy. ARG-007 aims to minimize the impact of these conditions and improve patient recovery by targeting specific molecular pathways involved in neuronal survival. The drug is intended for administration by first responders to protect brain tissue against damage during the acute phase of injury, with the potential to enhance recovery longer term. ARG-007 has demonstrated safety and tolerability in a Phase 1 clinical trial and is currently in Phase 2 clinical trials for acute ischaemic stroke patients.
Target Audience
The primary target audience includes patients at risk of or experiencing stroke and other acute brain injuries, as well as first responders and medical professionals involved in their immediate care.
Features
- Novel neuroprotective peptide therapeutic (ARG-007)
- Demonstrated reduction in brain cell death in pre-clinical animal models of stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy
- Proven safe and well-tolerated in a Phase 1 clinical trial in healthy human volunteers
- Currently in Phase 2 clinical trials for safety and efficacy in acute ischaemic stroke patients
- Potential for administration by first responders in acute brain injury scenarios